Walter & Keenan Wealth Management LLC IN ADV Has $345,000 Stock Holdings in Novartis AG (NYSE:NVS)

Walter & Keenan Wealth Management LLC IN ADV lowered its position in shares of Novartis AG (NYSE:NVS) by 14.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,550 shares of the company’s stock after selling 600 shares during the quarter. Walter & Keenan Wealth Management LLC IN ADV’s holdings in Novartis were worth $345,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Fisher Asset Management LLC grew its holdings in shares of Novartis by 15.7% in the 3rd quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock valued at $196,225,000 after buying an additional 231,851 shares during the period. FMR LLC grew its stake in Novartis by 5.5% in the third quarter. FMR LLC now owns 1,353,412 shares of the company’s stock valued at $155,669,000 after acquiring an additional 70,314 shares during the period. Natixis Advisors LLC grew its stake in Novartis by 2.9% in the third quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock valued at $107,986,000 after acquiring an additional 26,317 shares during the period. Bank of Montreal Can increased its holdings in shares of Novartis by 18.7% in the third quarter. Bank of Montreal Can now owns 780,980 shares of the company’s stock worth $90,289,000 after acquiring an additional 123,077 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Novartis by 128.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 528,682 shares of the company’s stock worth $51,554,000 after purchasing an additional 296,890 shares during the period. Institutional investors own 13.12% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on NVS. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. StockNews.com raised shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday. BMO Capital Markets boosted their price objective on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Finally, Deutsche Bank Aktiengesellschaft upgraded Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $123.38.

Novartis Stock Down 0.8 %

Shares of NVS stock opened at $106.17 on Monday. The firm’s fifty day moving average price is $100.32 and its two-hundred day moving average price is $108.40. The company has a current ratio of 1.04, a quick ratio of 0.90 and a debt-to-equity ratio of 0.48. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The firm has a market capitalization of $217.00 billion, a P/E ratio of 18.06, a PEG ratio of 1.70 and a beta of 0.58.

Novartis (NYSE:NVS) last released its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, equities analysts predict that Novartis AG will post 8.42 EPS for the current fiscal year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.